Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo
Curie: The Oncology Brief by Curie: The Platform for HCPs
Episode notes
Love what you hear? Download the Curie app from the App Store today.
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights!
Keywords
OncologyTreatmentCancer diagnosticsHCPsDoctorsUSAASHALLCLL